- Home
- MOLN vs IDR Comparison
MOLN vs IDR Comparison
Compare MOLN & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- IDR
- Stock Information
- Founded
- MOLN 2004
- IDR 1996
- Country
- MOLN Switzerland
- IDR United States
- Employees
- MOLN N/A
- IDR N/A
- Industry
- MOLN
- IDR Precious Metals
- Sector
- MOLN
- IDR Basic Materials
- Exchange
- MOLN Nasdaq
- IDR Nasdaq
- Market Cap
- MOLN 136.1M
- IDR 154.1M
- IPO Year
- MOLN 2021
- IDR N/A
- Fundamental
- Price
- MOLN $3.76
- IDR $13.05
- Analyst Decision
- MOLN
- IDR Strong Buy
- Analyst Count
- MOLN 0
- IDR 1
- Target Price
- MOLN N/A
- IDR $17.50
- AVG Volume (30 Days)
- MOLN 2.0K
- IDR 370.4K
- Earning Date
- MOLN 08-25-2025
- IDR 07-29-2025
- Dividend Yield
- MOLN N/A
- IDR N/A
- EPS Growth
- MOLN N/A
- IDR 144.40
- EPS
- MOLN N/A
- IDR 0.62
- Revenue
- MOLN $2,525,030.00
- IDR $27,144,971.00
- Revenue This Year
- MOLN N/A
- IDR $9.76
- Revenue Next Year
- MOLN $866.67
- IDR N/A
- P/E Ratio
- MOLN N/A
- IDR $21.00
- Revenue Growth
- MOLN N/A
- IDR 67.42
- 52 Week Low
- MOLN $3.36
- IDR $9.58
- 52 Week High
- MOLN $12.22
- IDR $19.75
- Technical
- Relative Strength Index (RSI)
- MOLN 49.47
- IDR 43.92
- Support Level
- MOLN $3.71
- IDR $12.40
- Resistance Level
- MOLN $3.89
- IDR $13.40
- Average True Range (ATR)
- MOLN 0.16
- IDR 0.60
- MACD
- MOLN 0.01
- IDR -0.07
- Stochastic Oscillator
- MOLN 41.27
- IDR 27.20
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.